Influenza A viruses circulated in Europe from September 2023 to January 2024, with influenza A(H1N1)pdm09 predominance. We provide interim 2023/24 influenza vaccine effectiveness (IVE) estimates from two European studies, covering 10 countries across primary care (EU -PC) and hospital (EU -H) settings. Interim IVE was higher against A(H1N1)pdm09 than A(H3N2): EU -PC influenza A(H1N1)pdm09 IVE was 53% (95% CI: 41 to 63) and 30% (95% CI: -3 to 54) against influenza A(H3N2). For EU -H, these were 44% (95% CI: 30 to 55) and 14% (95% CI: -32 to 43), respectively.
MAUREL, Marine; Jennifer HOWARD; Esther KISSLING; Francisco POZO; Gloria PEREZ-GIMENO; Silke BUDA; Noemie SEVE; Adele MCK-ENNA; Adam MEIJER; Ana Paula RODRIGUES; Ivan MARTINEZ-BAZ; Ivan MLINARIC; Neus LATORRE-MARGALEF; Gergo TURI; Mihaela LAZAR; Clara MAZAGATOS; Aitziber ECHEVERRIA; Stephen ABELA; Marc BOURGEOIS; Ausenda MACHADO; Ralf DUERRWALD; Goranka PETROVIC; Beatrix OROSZI; Ligita JANCORIENE; Alexandru MARIN; Petr HUSA; Roisin DUFFY; Frederika DIJKSTRA; Virtudes Gallardo GARCIA; Luise GOERLITZ; Vincent ENOUF; Charlene BENNETT; Mariette HOOIVELD; Raquel GUIOMAR; Camino TROBAJO-SANMARTIN; Vesna Visekruna VUCINA; Tove Samuelsson HAGEY; Ana Sofia Lameiras AZEVEDO; Jesus CASTILLA; Gerd XUEREB; Benedicte DELAERE; Veronica GOMEZ; Kristin TOLKSDORF; Sabrina BACCI; Nathalie NICOLAY; Marlena KACZMAREK a MC Rose ANGELA. Interim 2023/24 influenza A vaccine effectiveness: VEBIS European primary care and hospital multicentre studies, September 2023 to January 2024. EUROSURVEILLANCE. STOCKHOLM: EUR CENTRE DIS PREVENTION & CONTROL, 2024, roč. 29, č. 8, s. 1-8. ISSN 1025-496X. Dostupné z: https://doi.org/10.2807/1560-7917.ES.2024.29.8.2400089.
@article{2378957, author = {Maurel, Marine and Howard, Jennifer and Kissling, Esther and Pozo, Francisco and PerezandGimeno, Gloria and Buda, Silke and Seve, Noemie and McKandenna, Adele and Meijer, Adam and Rodrigues, Ana Paula and MartinezandBaz, Ivan and Mlinaric, Ivan and LatorreandMargalef, Neus and Turi, Gergo and Lazar, Mihaela and Mazagatos, Clara and Echeverria, Aitziber and Abela, Stephen and Bourgeois, Marc and Machado, Ausenda and Duerrwald, Ralf and Petrovic, Goranka and Oroszi, Beatrix and Jancoriene, Ligita and Marin, Alexandru and Husa, Petr and Duffy, Roisin and Dijkstra, Frederika and Garcia, Virtudes Gallardo and Goerlitz, Luise and Enouf, Vincent and Bennett, Charlene and Hooiveld, Mariette and Guiomar, Raquel and TrobajoandSanmartin, Camino and Vucina, Vesna Visekruna and Hagey, Tove Samuelsson and Azevedo, Ana Sofia Lameiras and Castilla, Jesus and Xuereb, Gerd and Delaere, Benedicte and Gomez, Veronica and Tolksdorf, Kristin and Bacci, Sabrina and Nicolay, Nathalie and Kaczmarek, Marlena and Angela, MC Rose}, article_location = {STOCKHOLM}, article_number = {8}, doi = {https://doi.org/10.2807/1560-7917.ES.2024.29.8.2400089}, keywords = {Influenza A vaccine effectiveness; European primary care; hospital multicentre studies}, language = {eng}, issn = {1025-496X}, journal = {EUROSURVEILLANCE}, title = {Interim 2023/24 influenza A vaccine effectiveness: VEBIS European primary care and hospital multicentre studies, September 2023 to January 2024}, url = {https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2024.29.8.2400089}, volume = {29}, year = {2024} }
TY - JOUR ID - 2378957 AU - Maurel, Marine - Howard, Jennifer - Kissling, Esther - Pozo, Francisco - Perez-Gimeno, Gloria - Buda, Silke - Seve, Noemie - McK-enna, Adele - Meijer, Adam - Rodrigues, Ana Paula - Martinez-Baz, Ivan - Mlinaric, Ivan - Latorre-Margalef, Neus - Turi, Gergo - Lazar, Mihaela - Mazagatos, Clara - Echeverria, Aitziber - Abela, Stephen - Bourgeois, Marc - Machado, Ausenda - Duerrwald, Ralf - Petrovic, Goranka - Oroszi, Beatrix - Jancoriene, Ligita - Marin, Alexandru - Husa, Petr - Duffy, Roisin - Dijkstra, Frederika - Garcia, Virtudes Gallardo - Goerlitz, Luise - Enouf, Vincent - Bennett, Charlene - Hooiveld, Mariette - Guiomar, Raquel - Trobajo-Sanmartin, Camino - Vucina, Vesna Visekruna - Hagey, Tove Samuelsson - Azevedo, Ana Sofia Lameiras - Castilla, Jesus - Xuereb, Gerd - Delaere, Benedicte - Gomez, Veronica - Tolksdorf, Kristin - Bacci, Sabrina - Nicolay, Nathalie - Kaczmarek, Marlena - Angela, MC Rose PY - 2024 TI - Interim 2023/24 influenza A vaccine effectiveness: VEBIS European primary care and hospital multicentre studies, September 2023 to January 2024 JF - EUROSURVEILLANCE VL - 29 IS - 8 SP - 1-8 EP - 1-8 PB - EUR CENTRE DIS PREVENTION & CONTROL SN - 1025496X KW - Influenza A vaccine effectiveness KW - European primary care KW - hospital multicentre studies UR - https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2024.29.8.2400089 N2 - Influenza A viruses circulated in Europe from September 2023 to January 2024, with influenza A(H1N1)pdm09 predominance. We provide interim 2023/24 influenza vaccine effectiveness (IVE) estimates from two European studies, covering 10 countries across primary care (EU -PC) and hospital (EU -H) settings. Interim IVE was higher against A(H1N1)pdm09 than A(H3N2): EU -PC influenza A(H1N1)pdm09 IVE was 53% (95% CI: 41 to 63) and 30% (95% CI: -3 to 54) against influenza A(H3N2). For EU -H, these were 44% (95% CI: 30 to 55) and 14% (95% CI: -32 to 43), respectively. ER -
MAUREL, Marine; Jennifer HOWARD; Esther KISSLING; Francisco POZO; Gloria PEREZ-GIMENO; Silke BUDA; Noemie SEVE; Adele MCK-ENNA; Adam MEIJER; Ana Paula RODRIGUES; Ivan MARTINEZ-BAZ; Ivan MLINARIC; Neus LATORRE-MARGALEF; Gergo TURI; Mihaela LAZAR; Clara MAZAGATOS; Aitziber ECHEVERRIA; Stephen ABELA; Marc BOURGEOIS; Ausenda MACHADO; Ralf DUERRWALD; Goranka PETROVIC; Beatrix OROSZI; Ligita JANCORIENE; Alexandru MARIN; Petr HUSA; Roisin DUFFY; Frederika DIJKSTRA; Virtudes Gallardo GARCIA; Luise GOERLITZ; Vincent ENOUF; Charlene BENNETT; Mariette HOOIVELD; Raquel GUIOMAR; Camino TROBAJO-SANMARTIN; Vesna Visekruna VUCINA; Tove Samuelsson HAGEY; Ana Sofia Lameiras AZEVEDO; Jesus CASTILLA; Gerd XUEREB; Benedicte DELAERE; Veronica GOMEZ; Kristin TOLKSDORF; Sabrina BACCI; Nathalie NICOLAY; Marlena KACZMAREK a MC Rose ANGELA. Interim 2023/24 influenza A vaccine effectiveness: VEBIS European primary care and hospital multicentre studies, September 2023 to January 2024. \textit{EUROSURVEILLANCE}. STOCKHOLM: EUR CENTRE DIS PREVENTION \&{} CONTROL, 2024, roč.~29, č.~8, s.~1-8. ISSN~1025-496X. Dostupné z: https://doi.org/10.2807/1560-7917.ES.2024.29.8.2400089.